Biology Reference
In-Depth Information
59. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the
breaks: Chk1 inhibitors as cancer therapeutics.
Trends Mol Med
2011;
17
:88
interact synergistically with UCN-01 to induce mitochondrial
dysfunction and apoptosis in human leukemia cells.
Cancer Res
2001;
61
:5106
96.
60. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin
B complex by the human WEE1 tyrosine kinase.
Science
1992;
257
:1955
e
15.
81. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01,
7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-
dependent kinases and reduces the phosphorylation of the reti-
noblastoma susceptibility gene product in A549 human lung
cancer cell line.
Biochem Biophys Res Commun
1996;
219
:778
e
7.
61. Pines J. Four-dimensional control of the cell cycle.
Nat Cell Biol
1999;
1
:E73
e
9.
62. Heald R, McLoughlin M, McKeon F. Human wee1 maintains
mitotic timing by protecting the nucleus from cytoplasmically
activated Cdc2 kinase.
Cell
1993;
74
:463
83.
82. Akinaga S, Sugiyama K, Akiyama T. UCN-01 (7-hydroxystaur-
osporine) and other indolocarbazole compounds: a new genera-
tion of anti-cancer agents for the new century.
Anticancer Drug
Des
2000;
15
:43
e
e
74.
63. Krek W, Nigg EA. Mutations of p34cdc2 phosphorylation sites
induce premature mitotic events in HeLa cells: Evidence for
a double block to p34cdc2 kinase activation in vertebrates.
EMBO
J
1991;
10
:3331
e
52.
83. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M.
Antitumor activity of UCN-01, a selective inhibitor of protein
kinase C, in murine and human tumor models.
Cancer Res
1991;
51
:4888
e
41.
64. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the
p34cdc2 protein kinase in vertebrates.
EMBO J
1991;
10
:3321
e
92.
84. Bhonde MR, Hanski M-L, Magrini R. The broad-range cyclin-
dependent kinase inhibitor UCN-01 induces apoptosis in colon
carcinoma cells through transcriptional suppression of the Bcl-xL
protein.
Oncogene
2005;
24
:148
e
9.
65. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphoryla-
tion in radiation-induced G2 arrest in human cells.
J Cell Biol
1996;
134
:963
e
70.
66. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle
regulation by the Chk2 protein kinase.
Science
1998;
282
:1893
e
56.
85. Sausville EA, Johnson J, Alley M, et al. Inhibition of CDKs as
a therapeutic modality.
Ann NY Acad Sci
2000;
910
:207
e
7.
67. Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1
checkpoint pathway in mammals: Linkage of DNA damage to
Cdk regulation through Cdc25.
Science
1997;
277
:1497
e
21.
86. Bunch RT, Eastman A. Enhancement of cisplatin-induced cyto-
toxicity by 7-hydroxystaurosporine (UCN-01), a new G2 check-
point inhibitor.
Clin Cancer Res
1996;
2
:791
e
501.
68. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1
kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15
phosphorylation.
EMBO J
1997;
16
:545
7.
87. Sugiyama K, Shimizu M, Akiyama T, et al. UCN-01 Selectively
enhances mitomycin C cytotoxicity in p53 defective cells which is
mediated through S and/or G(2) checkpoint abrogation.
Int J
Cancer
2000;
85
:703
e
e
54.
69. Raleigh JM, O'Connell MJ. The G2 DNA damage checkpoint
targets both Wee1 and Cdc25.
J Cell Sci
2000;
113
:1727
e
9.
88. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in
combination with topotecan in patients with advanced solid
cancers: A Princess Margaret hospital phase II consortium study.
Ann Oncol
2006;
17
:334
e
36.
70. Lee J, Kumagai A, Dunphy WG. Positive regulation of Wee1 by
Chk1 and 14-3-3 proteins.
Mol Biol Cell
2000;
12
:551
e
63.
71. Wang Y, Li J, Booher RN, et al. Radiosensitization of p53 mutant
cells by PD0166285, a novel G(2) checkpoint abrogator.
Cancer Res
2001;
61
:8211
e
40.
89. Perez RP, Lewis LD, Beelen AP, et al. Modulation of cell cycle
progression in human tumors: A pharmacokinetic and tumor
molecular pharmacodynamic study of cisplatin plus the Chk1
inhibitor UCN-01 (NSC 638850).
Clin Cancer Res
2006;
12
:7079
e
7.
72. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1
and Myt1 by RNA interference abrogates G2 checkpoint and
induces apoptosis.
Cancer Biol Ther
2004;
3
:305
e
85.
90. Sampath D, Cortes J, Estrov Z, et al. Pharmacodynamics of
cytarabine alone and in combination with 7-hydroxystaur-
osporine (UCN-01) in AML blasts in vitro and during a clinical
trial.
Blood
2006;
107
:2517
e
13.
73. Hirai H, Iwasawa Y, Okada M, et al. Small molecule inhibition of
Wee1 kinase by MK-1775 selectively sensitizes p53-deficient
tumor
e
cells
to DNA-damaging agents.
Mol Cancer Ther
24.
91. Gandara DR, Lara PN, Longmate J, et al. The cyclin-dependent
kinase (CDK) Inhibitor UCN-01 plus cisplatin in advanced solid
tumors: A California Cancer Consortium Phase I Trial.
Proc Am
Soc Clin Oncol (ASCO)
2003;
22
. Abst 987.
92. Kummar S, Guiterrez ME, Gardener ER, et al. A phase I trial of
UCN-01 and prednisone in patients with refractory solid tumors
and lymphomas.
Cancer Chemother Pharmacol
2010;
65
:383
e
3000.
74. Lau CC, Pardee AB. Mechanism by which caffeine potentiates
lethality of nitrogen mustard.
Proc Natl Acad Sci USA
1982;
79
:2942
2009;
8
:2992
e
6.
75. Das SK, Lau CC, Pardee AB. Abolition by cycloheximide of
caffeine-enhanced lethality of alkylating agents in hamster cells.
Cancer Res
1982;
42
:4499
e
504.
76. Musk SR, Steel GG. Override of the radiation-induced mitotic
block in human tumor cells by methylxanthines and its rela-
tionship to the potentiation of cytotoxicity.
Int J Radiat Biol
1990;
57
:1105
e
9.
93. Mathews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation
of S-phase checkpoint enhances the anti-tumor activity of gem-
citabine in vivo.
Cell Cycle
2007;
6
:104
e
10.
94. Clary DO. Inhibition of CHKs in a leukemia model abrogates
DNA damage checkpoints and promotes mitotic catastrophe.
Proc Am Assoc Cancer Res
2007;
48
. Abst 5385.
95. Castedo M, Perfettinin J-L, Roumier T, et al. Cell death by mitotic
catastrophe: a molecular definition.
Oncogene
2004;
23
:2825
e
12.
77. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB,
Dezube Jr B. Efficacy of pentoxyfylline as a modulator of alky-
lating agent activity
in vitro
and
in vivo
.
Anticancer Res
1991;
11
:
1555
e
60.
78. Ribeiro JC, Barnetson AR, Jackson P, Ow K, Links M, Russell PJ.
Caffeine-increased radiosensitivity is not dependent on a loss of
G2/M arrest or apoptosis in bladder cancer cell lines.
Int J Radiat
Biol
1999;
75
:481
e
37.
96. Matthews DJ. Dissecting the roles of Chk1 and Chk2 in mitotic
catastrophe using chemical genetics.
Eur J Cancer
2006;
4
. Abst
344.
97. Tse AN, Yazji S, Naing A, et al. Phase 1 study of XL844, a novel
Chk1 and Chk2 kinase inhibitor, in combination with gemcita-
bine in subjects with advanced malignancies.
Eur J Cancer Suppl
2008;
6
. Abst 395.
98. Lyne PD, Kenny PW, Cosgrove DA, et al. Identification of
compounds with nanomolar binding affinity for checkpoint
e
92.
79. Moser BA, Brondello J-M, Baber-Furnari B, Russell P. Mechanism
of caffeine-induced checkpoint override in fission yeast.
Mol Cell
Biol
2000;
20
:4288
e
94.
80. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the
mitogen-activated protein kinase (MAPK) kinase/MAPK cascade
e
